Tempus is a Chicago-based leading technology company that is ushering precision medicine as a means to advance cancer care. It collects and analyzes molecular and clinical data. It aims to build the world’s largest library of cancer care information and place that database at the fingertips of physicians.
Tempus is constantly expanding its repertoire of tools by which it adds to the ongoing battle against cancer. The company is well positioned to tackle one of the biggest problems that is plaguing the health care industry today, namely a plethora of disorganized and siloed patient information that could provide insight into future patient care.
Tempus is rich with collaborations, as well. It is currently working with nearly all of the nation’s National Cancer Institute-designated Comprehensive Cancer Centers as well as several prestigious academic and health care institutions whose oncologists send their patients to Tempus for sequencing.
Tempus most recently established a collaboration with Mary Crowley Research with the objective of expanding research options for lung cancer patents. As part of the collaboration, Tempus will be a preferred provider for Mary Crowley Cancer Research to perform molecular sequencing, analysis and provide clinical support for patients diagnosed with lung cancer.
Lung cancer is one of the most common cancers in the United States, affecting both men and women. When detected in time and when it is still localized within the lungs (either Stage I or Stage II), the five-year survival rate is 56 percent. However, less than half of lung cancer cases (~43 percent) are actually diagnosed at these favorable disease stages as signs and symptoms only become apparent after the disease has advanced beyond them.
According to the Director of Clinical Trial Development at Mary Crowley, “Unfortunately, a match is not always found, which leads providers to test for gene alterations specific to clinical trials. This process although key in personalizing and expanding cancer treatment options, is often lengthy and requires extra tissue.”
James Strauss, MD, the Executive Scientific Director at Mary Crowley is optimistic about the collaboration, stating that his team is viewing it as a means to be more efficient about incorporating their available studies and finding the best therapeutic solution for lung cancer patients.
Eric Lefkofsky founded Tempus in 2015. The company uses an interactive and analytical machine learning platform that leverages data from biological models, proteomics and single cell genomics. The company organizes unstructured data, particularly focusing on combining clinical and molecular cancer data and makes it available to physicians so that they can make more informed and more personalized cancer care decisions. Lefkofsky’s ultimate goal with Tempus is to enable each patient to benefit from the treatment of those who came before. In other words, his goal is a personalized cancer care approach.
About Eric Lefkofsky
Lefkofsky is one of Chicago’s most influential entrepreneurs whose venture repertoire encompasses ventures such as Lightbank, Groupon, Mediaocean, Echo Global Logistics and InnerWorkings. Lefkofsky is also a philanthropist, and as such is involved in several organizations that focus on improving the lives of those in need. He is the Trustee of the Lurie Children’s Hospital in Chicago, the Art Institute of Chicago, The Museum of Science and Industry and World Business Chicago. He also serves as the Board of Trustees’ Chairman of Chicago’s Steppenwolf Theatre Company. He and his wife Liz co-chair the Lefkofsky Family Foundation and in 2013, the two joined the Giving Pledge, whose members commit to donating half their wealth to philanthropic causes. Lefkofsky currently holds an adjunct professorship at the University of Chicago’s Booth School of Business. Lefkofsky obtained his Juris Doctor at the University of Michigan Law School. He is the author of Accelerated Disruption: Understanding the True Speed of Innovation.
For more information on Eric Lefkofsky, please visit lefkofsky.com, LinkedIn: ericlefkofsky, Twitter: @lefkofsky or Facebook: @eplefkofsky. For more information on Tempus, please visit tempus.com, Facebook: @TempusLabs and Twitter: @TempusLabs.
About Mary Crowley Cancer Research
Mary C. Crowley was a Dallas entrepreneur who founded the Mary Crowley Cancer Research driven by the belief that cancer patients needed access to better cancer treatments. Founded in 1997, the cancer center became a place that explored investigational vaccine, gene and cellular therapies, and as such it expanded treatment options for adult cancer patients. Having begun these novel therapeutic approaches so early is why Mary Crowley was considered a leader in what would later be known as personalized and precision medicine. The center is headquartered in Dallas, TX, and has several other satellite sites throughout the U.S. With an ongoing objective to offer novel discoveries in genomic and immune therapies in innovative ways, the aim of the center is to positively affect the care of cancer patients and to transform their cancer into a manageable disease. Mary Crowley Cancer Research is currently collaborating with 21 of the top 25 pharmaceutical companies, drawing patients from all of the U.S. and the world.